Rifaximin-extended intestinal release induces remission in patients with moderately active crohn's disease

Gastroenterology

Volumn 142, Issue 3, 2012, Pages 473-481.e4

  Prantera, Cosimo ^a   Lochs, Herbert ^b   Grimaldi, Maria ^c   Danese, Silvio ^d   Scribano, Maria Lia ^a   Gionchetti, Paolo ^e  

^a SAN CAMILLO FORLANINI HOSPITAL   (Italy)

^b INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^c Alfa Wassermann SpA   (Italy)

^d HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^e UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

IBD; Inflammation; Intestinal Microbiota; Nonabsorbed Antibiotic

Indexed keywords

AZATHIOPRINE; C REACTIVE PROTEIN; MERCAPTOPURINE; MESALAZINE; METHOTREXATE; PLACEBO; RIFAXIMIN;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; CLOSTRIDIUM DIFFICILE INFECTION; CONTROLLED RELEASE FORMULATION; CONTROLLED STUDY; CROHN DISEASE; CROHN DISEASE ACTIVITY INDEX; DISEASE ACTIVITY; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG FEVER; DRUG SAFETY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; EXTENDED INTESTINAL RELEASE FORMULATION; FEMALE; FLATULENCE; FOLLOW UP; HEADACHE; HUMAN; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REMISSION; RESPIRATORY TRACT INFECTION; RHINOPHARYNGITIS; SCORING SYSTEM; SIDE EFFECT; TREATMENT DURATION; TREATMENT OUTCOME; VOMITING;

EID: 84856960246     PISSN: 00165085     EISSN: 15280012     Source Type: Journal    
DOI: 10.1053/j.gastro.2011.11.032     Document Type: Article

References (47)

1. F. Scaldaferri, C. Fiocchi Inflammatory bowel disease: progress and current concepts of etiopathogenesis J Dig Dis 8 2007 171 178
2. R.B. Sartor Microbial influences in inflammatory bowel diseases Gastroenterology 134 2008 577 594
3. N. Barnich, A. Darfeuille-Michaud Role of bacteria in the etiopathogenesis of inflammatory bowel disease World J Gastroenterol 13 2007 5571 5576
4. A.J. Macpherson, N.L. Harris Interaction between commensal intestinal bacteria and the immune system Nat Rev Immunol 4 2004 478 485
5. G. Rogler The effects of NOD2/CARD15 mutations on the function of the intestinal barrier J Crohns Colitis 1 2007 53 60
6. M. Perencevich, R. Burakoff Use of antibiotics in the treatment of inflammatory bowel disease Inflamm Bowel Dis 12 2006 651 664
7. G.E. Wild The role of antibiotics in the management of Crohn's disease Inflamm Bowel Dis 10 2004 321 323
8. C. Prantera What role do antibiotics have in the treatment of IBD? Nat Clin Pract Gastroenterol Hepatol 5 2008 670 671
9. N.S. Ambrose, R.N. Allan, M.R. Keighley Antibiotic therapy for treatment in relapse of intestinal Crohn's disease A prospective randomized study Dis Colon Rectum 28 1985 81 85
10. G.L. Arnold, M.R. Beaves, V.O. Pryjdun Preliminary study of ciprofloxacin in active Crohn's disease Inflamm Bowel Dis 8 2002 10 15
11. P. Blichfeldt, J.P. Blomhoff, E. Myhre Metronidazole in Crohn's disease A double blind cross-over clinical trial Scand J Gastroenterol 13 1978 123 127
12. J.F. Colombel, M. Lemann, M. Cassagnou A controlled trial comparing ciprofloxacin with mesalazine for the treatment of active Crohn's disease Groupe d'Etudes Therapeutiques des Affections Inflammatoires Digestives (GETAID) Am J Gastroenterol 94 1999 674 678
13. K. Leiper, A.I. Morris, J.M. Rhodes Open label trial of oral clarithromycin in active Crohn's disease Aliment Pharmacol Ther 14 2000 801 806
14. C. Prantera, F. Zannoni, M.L. Scribano An antibiotic regimen for the treatment of active Crohn's disease: a randomized, controlled clinical trial of metronidazole plus ciprofloxacin Am J Gastroenterol 91 1996 328 332
15. C. Prantera, E. Berto, M.L. Scribano Use of antibiotics in the treatment of active Crohn's disease: experience with metronidazole and ciprofloxacin Ital J Gastroenterol Hepatol 30 1998 602 606
16. A.H. Steinhart, B.G. Feagan, C.J. Wong Combined budesonide and antibiotic therapy for active Crohn's disease: a randomized controlled trial Gastroenterology 123 2002 33 40
17. L. Sutherland, J. Singleton, J. Sessions Double blind, placebo controlled trial of metronidazole in Crohn's disease Gut 32 1991 1071 1075
18. B. Ursing, T. Alm, F. Barany A comparative study of metronidazole and sulfasalazine for active Crohn's disease: the cooperative Crohn's disease study in Sweden II. Result Gastroenterology 83 1982 550 562
19. R. Rahimi, S. Nikfar, A. Rezaie A meta-analysis of broad-spectrum antibiotic therapy in patients with active Crohn's disease Clin Ther 28 2006 1983 1988
20. A. Dignass, G. Van Assche, J.O. Lindsay European Crohn's and Colitis Organisation (ECCO) The second European evidence-based consensus on the diagnosis and management of Crohn's disease: current management J Crohns Colitis 4 2010 28 62
21. L.F. Duffy, F. Daum, S.E. Fisher Peripheral neuropathy in Crohn's disease patients treated with metronidazole Gastroenterology 88 1985 681 684
22. Z.D. Jiang, S. Ke, E. Palazzini In vitro activity and faecal concentration of Rifaximin after oral administration Antimicrob Agents Chemother 44 2000 2205 2206
23. Z.D. Jiang, H.L. DuPont Rifaximin: in vitro and in vivo antibacterial activitya review Chemotherapy 51 Suppl 1 2005 67 72
24. H. Gomi, Z.D. Jiang, J.A. Adachi In vitro antimicrobial susceptibility testing of bacterial enteropathogens causing traveler's diarrhea in four geographic regions Antimicrob Agents Chemother 45 2001 212 216
25. W.W. Hoover, E.H. Gerlach, D.J. Hoban Antimicrobial activity and spectrum of Rifaximin, a new topical rifamycin derivative Diagn Microbiol Infect Dis 16 1993 111 118
26. C. Scarpignato, I. Pelosini Experimental and clinical pharmacology of Rifaximin, a gastrointestinal selective antibiotic Digestion 73 Suppl 1 2006 13 27
27. M. Pimentel, A. Lembo, W.D. Chey Target Study Group Rifaximin therapy for patients with irritable bowel syndrome without constipation N Engl J Med 364 2011 22 32
28. N.M. Bass, K.D. Mullen, A. Sanyal Rifaximin treatment in hepatic encephalopathy N Engl J Med 362 2010 1071 1081
29. Z.D. Jiang, S. Ke, H.L. Dupont Rifaximin-induced alteration of virulence of diarrhoea-producing Escherichia coli and Shigella sonnei Int J Antimicrob Agents 35 2010 278 281
30. E.L. Brown, Q. Xue, Z.D. Jiang Pretreatment of epithelial cells with Rifaximin alters bacterial attachment and internalization profiles Antimicrob Agents Chemother 54 2010 388 396
31. J. Cheng, Y.M. Shah, X. Ma Therapeutic role of Rifaximin in inflammatory bowel disease: clinical implication of human pregnane X receptor activation J Pharmacol Exp Ther 335 2010 32 41
32. C. Prantera, H. Lochs, M. Campieri Antibiotic treatment of Crohn's disease: results of a multicentre, double blind, randomized, placebo-controlled trial with rifaximin Aliment Pharmacol Ther 23 2006 1117 1125
33. S. Holm A simple sequentially rejective multiple test procedure Scand J Stat 6 1979 65 70
34. A. Agresti, C.R. Mehta, N.R. Patel Exact inference for contingency tables with ordered categories J Am Stat Assoc 85 1990 453 458
35. C. Su, G.R. Lichtenstein, K. Krok A meta-analysis of the placebo rates of remission and response in clinical trials of active Crohn's disease Gastroenterology 126 2004 1257 1269
36. E.C. Lauritano, M. Gabrielli, E. Scarpellini Antibiotic therapy in small intestinal bacterial overgrowth: rifaximin versus metronidazole Eur Rev Med Pharmacol Sci 13 2009 111 116
37. E. Scarpellini, M. Gabrielli, C.E. Lauritano High dose rifaximin for the treatment of small intestinal bacterial overgrowth Aliment Pharmacol Ther 25 2007 781 786
38. J. Tack Antibiotic therapy for the irritable bowel syndrome N Engl J Med 364 2011 81 82
39. G. D'Haens, F. Baert, G. van Assche Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial Lancet 371 2008 660 667
40. J.F. Colombel, W.J. Sandborn, W. Reinisch Infliximab, azathioprine, or combination therapy for Crohn's disease N Engl J Med 362 2010 1383 1395
41. W.J. Sandborn, B.G. Feagan, S. Stoinov PRECISE I Study Investigators Certolizumab Pegol for the treatment of Crohn's disease N Engl J Med 357 2007 228 238
42. S.W. Glickman, J.G. McHutchison, E.D. Peterson Ethical and scientific implications of the globalization of clinical research N Engl J Med 360 2009 816 823
43. S. Schreiber, P. Rutgeerts, R.N. Fedorak A randomized, placebo-controlled trial of Certolizumab Pegol (CDP870) for treatment of Crohn's disease Gastroenterology 129 2005 807 818
44. W.J. Sandborn, J.F. Colombel, R. Enns Natalizumab induction and maintenance therapy for Crohn's Disease N Engl J Med 353 2005 1912 1925
45. W.J. Sandborn, S. Schreiber, B.G. Feagan Certolizumab Pegol for active Crohn's Disease: a placebo-controlled, randomized trial Clin Gastroenterol Hepatol 9 2011 670 678
46. P. Patrick Basu, A. Dinani, K. Rayapudi Rifaximin therapy for metronidazole-unresponsive Clostridium difficile infection: a prospective pilot trial Ther Adv Gastroenterol 3 2010 221 225
47. A. Marchese, A. Salerno, A. Pesce In vitro activity of rifaximin, metronidazole and vancomycin against Clostridium Difficile and the rate of selection of spontaneously resistant mutants against representative anaerobic and aerobic bacteria, including ammonia-producing species Chemotherapy 46 2000 253 266